Based on the results that ZM241385 treatment, but not CGS21680, reversed the TGF-β1-induced increase in profibrotic markers, we sought to discover therapeutic candidates for the treatment of hepatic fibrosis in MASH conditions through inhibition of the A2aAR signaling pathway. Here, TGFB1 is linked to Hepatic fibrosis.